TB-500 (Thymosin Beta-4 Fragment) Evidence Grade: B+
TB-500 is a synthetic peptide based on the active region of thymosin beta-4 (Tb4), a 43-amino-acid protein that is one of the most abundant and highly conserved polypeptides in the human body. Thymosin beta-4 is found in virtually all human cells and tissues, where it serves as the primary intracellular G-actin sequestering protein — a critical regulator of the actin cytoskeleton that controls cell shape, motility, and migration.
The key active sequence of TB-500 is the 17-amino-acid actin-binding domain centered on the tetrapeptide LKKTETQ (amino acids 17-23), which drives the compound's primary biological activity: promoting cell migration into wound sites, stimulating angiogenesis, and modulating inflammation. These properties have made TB-500 one of the most extensively studied tissue repair peptides in preclinical research, with particular attention to wound healing, cardiac repair, corneal healing, and musculoskeletal recovery.
Thymosin beta-4 has also been investigated in clinical trials under the pharmaceutical designation RGN-352 (RegeneRx Biopharmaceuticals) for cardiac repair following myocardial infarction and as RGN-259 (ophthalmic) for dry eye and corneal wound healing. These clinical programs provide some human data, though TB-500 as a research compound is primarily supported by preclinical evidence.
Table of Contents
Overview
Thymosin beta-4 (Tb4) was first isolated from calf thymus tissue in the 1960s by Allan Goldstein and colleagues at George Washington University as part of research into thymic hormone function. Initially believed to be exclusively a thymic peptide involved in T-cell maturation, subsequent research revealed that Tb4 is expressed ubiquitously throughout the body and is particularly abundant in platelets, wound fluid, and developing tissues [1].
The protein's primary intracellular function is sequestration of G-actin monomers, maintaining the pool of unpolymerized actin available for rapid cytoskeletal reorganization when cells need to migrate, divide, or change shape. This function places Tb4 at the center of the cellular machinery for tissue repair, as cell migration is the rate-limiting step in wound closure [2]. When tissue damage occurs, Tb4 is released from platelets and damaged cells, where it acts as an extracellular signaling molecule to recruit progenitor cells, promote blood vessel formation, and modulate inflammation.
TB-500, the synthetic research compound, replicates the active region of Tb4 responsible for these tissue repair properties. While the full 43-amino-acid Tb4 sequence includes additional domains (including regions involved in anti-apoptotic signaling), the LKKTETQ-containing fragment retains the majority of Tb4's documented biological activity. Research-grade TB-500 is typically supplied as a lyophilized powder for subcutaneous or intramuscular injection [3].
The compound has attracted significant attention in the veterinary field, particularly in equine sports medicine, where it has been widely used for injury recovery in racehorses. This veterinary use has provided substantial empirical data on efficacy and safety, though controlled equine studies are limited. In human research, the most advanced clinical programs involve RegeneRx Biopharmaceuticals' RGN-352 (cardiac) and RGN-259 (ophthalmic) formulations of synthetic thymosin beta-4.
Mechanism of Action
TB-500's primary mechanism is the sequestration of monomeric G-actin, controlling the availability of actin monomers for polymerization into F-actin filaments. When cells receive migration signals (e.g., from wound-derived chemokines), TB-500 releases sequestered G-actin for rapid F-actin polymerization at the leading edge of the cell. This drives formation of lamellipodia and filopodia — the cellular extensions required for directional migration into wound beds. The LKKTETQ domain is the minimal sequence required for this actin-binding activity [2][4].
TB-500 promotes the formation of new blood vessels through upregulation of VEGF, activation of endothelial cell migration, and promotion of endothelial tube formation. In models of ischemic tissue injury, Tb4 treatment increases capillary density in the peri-infarct zone, improving blood supply to damaged tissue. This angiogenic activity is synergistic with its cell migration effects — both endothelial cells and tissue progenitor cells require functional migration for vascular and tissue repair [5].
TB-500 reduces inflammatory signaling through suppression of NF-kB pathway activation and reduction of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). It also modulates the balance between M1 (pro-inflammatory) and M2 (anti-inflammatory/reparative) macrophage polarization, shifting the immune response toward a regenerative phenotype. In corneal injury models, Tb4 reduces inflammatory infiltrate and prevents excessive scarring [6].
Tb4 activates tissue-resident stem and progenitor cells, promoting their mobilization and differentiation into tissue-appropriate cell types. In cardiac models, Tb4 activates epicardial progenitor cells that can differentiate into cardiomyocytes and vascular smooth muscle cells, contributing to myocardial regeneration. This progenitor cell activation mechanism has been particularly well-characterized in cardiac repair research [7].
TB-500 promotes cell survival through inhibition of apoptotic pathways. It increases expression of the anti-apoptotic protein Akt (protein kinase B) and reduces caspase-3 activation. In cardiac ischemia-reperfusion models, Tb4 pretreatment reduces infarct size and cardiomyocyte death. These cytoprotective effects are mediated by both direct anti-apoptotic signaling and indirect protection through improved vascularization and reduced oxidative stress [8].
Research Timeline
Discovery. Allan Goldstein isolates a family of thymic peptides (thymosins) from calf thymus tissue at George Washington University. Thymosin beta-4 is identified as a major component.
Sequence determination. The complete 43-amino-acid sequence of thymosin beta-4 (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES) is established. Recognized as the most abundant member of the beta-thymosin family.
Actin-binding function elucidated. Tb4 is identified as the primary G-actin sequestering protein in mammalian cells. The LKKTETQ domain is mapped as the minimal actin-binding sequence. The protein's role shifts from thymic immune function to ubiquitous cellular housekeeping [2].
Wound healing and angiogenesis studies. Malinda et al. and Philp et al. demonstrate that Tb4 accelerates wound closure, promotes angiogenesis, and enhances keratinocyte migration in dermal wound models. The peptide's role as an extracellular repair signal is established [5].
Cardiac repair research. Bock-Marquette et al. (2004, Nature) demonstrate that Tb4 reduces infarct size and promotes cardiac function recovery after myocardial infarction in mice. Epicardial progenitor cell activation is identified as a key mechanism [7].
Corneal healing studies. RGN-259 (ophthalmic Tb4 formulation) enters clinical trials for dry eye disease and corneal wound healing. Phase II data shows improved corneal staining scores and symptom relief [9].
Equine use expands. TB-500 becomes widely used in equine sports medicine for tendon, ligament, and joint injury recovery. Several high-profile racing bans for TB-500 use bring the peptide to broader public attention.
Clinical development continues. RGN-352 cardiac program advances. Research community adoption of TB-500 for tissue repair protocols grows. WADA lists thymosin beta-4 as a prohibited substance. Combination studies with BPC-157 generate significant interest.
Clinical Evidence Grade: B+
Human Clinical Trials (Thymosin Beta-4 / RGN Formulations)
Multiple Phase II trials evaluating topical thymosin beta-4 (0.1%) eye drops for dry eye disease. Demonstrated statistically significant improvement in corneal staining scores, tear film breakup time, and patient-reported symptoms versus placebo. Well-tolerated with minimal adverse effects.
Phase I safety study of intravenous thymosin beta-4 in patients following acute myocardial infarction. Demonstrated safety and tolerability at multiple dose levels. Trends toward improved cardiac function endpoints (LVEF, infarct size) were observed but not powered for efficacy.
Key Preclinical Studies
Landmark study in Nature demonstrating that Tb4 reduces myocardial infarct size by ~50% in mice when administered after coronary artery ligation. Mechanism: activation of integrin-linked kinase (ILK), promoting cardiomyocyte survival and migration. First demonstration of Tb4's cardiac repair potential.
Demonstrated that Tb4 priming reactivates quiescent adult epicardial progenitor cells, enabling them to differentiate into cardiomyocytes and vascular cells. This finding established the potential for Tb4 to promote endogenous cardiac regeneration — a paradigm shift in cardiac repair thinking.
Full-thickness skin wound study in rats. Tb4 treatment significantly accelerated wound closure versus controls, with improved epithelialization, angiogenesis, and collagen deposition. Established the foundational evidence for Tb4's wound healing properties.
Demonstrated that Tb4 eye drops promote corneal epithelial wound healing and reduce inflammation in alkali-burn models. Enhanced corneal progenitor cell migration and reduced inflammatory infiltrate. Provided the basis for the RGN-259 clinical program.
Demonstrated that Tb4 promotes hair follicle stem cell migration and differentiation, accelerating hair growth in mouse models. The effect was mediated through activation of hair follicle bulge stem cells, suggesting potential applications in alopecia research.
Evidence Assessment
| Application | Evidence Volume | Quality | Consistency |
|---|---|---|---|
| Wound Healing (dermal) | 10+ preclinical | High | Consistent |
| Cardiac Repair | 8+ preclinical, Phase I human | High | Consistent |
| Corneal Healing | 5+ preclinical, Phase II human | High | Consistent |
| Musculoskeletal | 5+ preclinical | Moderate | Consistent |
| Hair Growth | 2-3 preclinical | Moderate | Preliminary |
Dosing & Administration
Research Dosing Protocol
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Loading Phase | 2.0-2.5 mg | 2x per week | 4-6 weeks |
| Maintenance Phase | 2.0-2.5 mg | 1x per week | 4-8 weeks |
| Intensive Loading (optional) | 5.0 mg | 2x per week | 2 weeks only |
Administration
- Route: Subcutaneous injection is the standard research route. Intramuscular injection is also used, particularly for localized musculoskeletal research.
- Injection site: Abdominal subcutaneous tissue (systemic) or near (not into) the target tissue for localized effects.
- Timing: No specific timing requirements. Can be administered at any time of day.
Reconstitution
TB-500 is typically supplied in 2 mg, 5 mg, or 10 mg lyophilized vials.
| Vial Size | BAC Water | Concentration | 2 mg Dose = | 2.5 mg Dose = |
|---|---|---|---|---|
| 2 mg | 1 mL | 2000 mcg/mL | 1.0 mL | N/A (use 2.5 mg vial) |
| 5 mg | 2 mL | 2500 mcg/mL | 0.8 mL | 1.0 mL |
| 10 mg | 2 mL | 5000 mcg/mL | 0.4 mL | 0.5 mL |
Use the Reconstitution Calculator for precise volume calculations.
Storage
- Lyophilized: -20°C for long-term. Room temperature for short periods (weeks).
- Reconstituted: 2-8°C (refrigerate). Use within 2-3 weeks. Do not freeze reconstituted solution.
Pharmacokinetics
| Parameter | Value | Notes |
|---|---|---|
| Half-Life | ~2-3 hours | Short; biological effects persist longer than plasma levels |
| Bioavailability (SubQ) | ~70-80% | Estimated from animal models |
| Onset of Action | Hours (cellular level) | Tissue-level effects visible at 3-7 days |
| Time to Peak (Tmax) | ~30-60 min (SubQ) | Rapid absorption |
| Metabolism | Proteolytic degradation (standard peptide metabolism) | |
| Elimination | Renal (amino acid fragments) | |
| Endogenous Levels | ~15-40 ng/mL | Tb4 is naturally present in all nucleated cells |
Key PK Notes
- Short half-life, sustained effects: Although TB-500 has a short plasma half-life (~2-3 hours), its biological effects persist well beyond plasma clearance. This is because Tb4 acts by triggering intracellular signaling cascades and gene expression changes that continue after the peptide is cleared. The downstream effects (cell migration, angiogenesis, gene expression) unfold over days to weeks.
- Dosing frequency rationale: The twice-weekly loading dose and once-weekly maintenance dose reflect the gap between the short plasma half-life and the longer duration of biological effects. More frequent dosing is used during loading to rapidly establish tissue-level concentrations sufficient to initiate repair cascades.
- Ubiquitous endogenous presence: Tb4 is naturally present at 15-40 ng/mL in plasma and is the most abundant small peptide in mammalian cells. Exogenous administration supplements this endogenous pool, particularly in tissues with acute injury where local Tb4 may be depleted.
Side Effects & Safety
Reported Effects (Preclinical / Anecdotal)
- Injection site redness or irritation (transient)
- Mild lethargy or fatigue (uncommon)
- Head rush or lightheadedness post-injection (rare)
- Localized tingling at injection site
- Temporary flu-like symptoms (rare, typically with high loading doses)
Theoretical / Precautionary Risks
- Potential promotion of pre-existing tumor growth (angiogenesis/cell migration concern) — no direct evidence in preclinical studies
- Unknown long-term effects of chronic exogenous administration
- Limited human safety data beyond Phase I/II clinical trials of pharmaceutical-grade Tb4
- Theoretical interaction with immune function at very high doses
Safety Profile: Thymosin beta-4 has demonstrated a favorable safety profile in Phase I/II clinical trials (RGN-352, RGN-259) with no dose-limiting toxicities identified. As an endogenous protein found in all nucleated cells, it has inherent biocompatibility. However, research-grade TB-500 may differ in purity and composition from pharmaceutical-grade Tb4, and long-term safety data in humans is limited.
Contraindications
- Active cancer or history of cancer (theoretical concern: angiogenesis and cell migration promotion could theoretically support tumor growth)
- Pregnancy and breastfeeding (no safety data)
- Active systemic infection (immune modulation concern)
- Children and adolescents (no safety data)
Stacking & Synergies
| Stack Partner | Synergy Rationale | Common Protocol | Evidence |
|---|---|---|---|
| BPC-157 | The most popular tissue repair stack. TB-500 drives cell migration (actin pathway) while BPC-157 promotes angiogenesis (VEGF/GH) and reduces inflammation (NF-kB). Together they address the full wound healing cascade. | TB-500 2.5 mg 2x/wk + BPC-157 250-500 mcg/day | High (mechanistic, widely used) |
| GHK-Cu | GHK-Cu promotes collagen synthesis, extracellular matrix remodeling, and anti-oxidant gene expression. Complements TB-500's cell migration with structural tissue maturation. | TB-500 SubQ + GHK-Cu topical or SubQ | Moderate (theoretical) |
| MK-677 | GH/IGF-1 elevation provides systemic anabolic support for tissue repair. MK-677 oral convenience + TB-500 SubQ = practical combined protocol. | TB-500 2.5 mg 2x/wk + MK-677 25 mg daily oral | Moderate (theoretical) |
| Ipamorelin / CJC-1295 | GH secretagogues enhance the anabolic environment. Pulsatile GH release supports collagen synthesis and tissue remodeling alongside TB-500's migration effects. | TB-500 2x/wk + Ipamorelin/CJC daily SubQ | Moderate (theoretical) |
Regulatory Status
| Jurisdiction | Status | Details |
|---|---|---|
| United States (FDA) | Not approved | TB-500 is a research chemical. Pharmaceutical-grade thymosin beta-4 (RGN-352, RGN-259) has IND status for specific indications. |
| WADA | Prohibited | Thymosin beta-4 is listed under S2.2 "Peptide Hormones, Growth Factors, Related Substances, and Mimetics" — prohibited in and out of competition. |
| Australia (Racing) | Prohibited in racing | Multiple racing jurisdictions worldwide have banned TB-500 use in competition animals, particularly horses. |
| European Union | Not approved | Research chemical classification. RGN-259 ophthalmic has been investigated in EU clinical sites. |
Note: Thymosin beta-4 / TB-500 is prohibited by WADA. Athletes subject to anti-doping testing should be aware that TB-500 is detectable and its use constitutes a doping violation. Research use should be conducted in compliance with applicable regulations.
Frequently Asked Questions
What is the difference between TB-500 and Thymosin Beta-4?
How does TB-500 promote tissue repair?
What is the typical TB-500 research dosing protocol?
Is TB-500 the same as thymosin alpha-1?
Can TB-500 and BPC-157 be used together?
References
- Goldstein AL, et al. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005;11(9):421-9. PMID: 16099219
- Safer D, Elzinga M, Nachmias VT. "Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable." J Biol Chem. 1991;266(7):4029-32. PMID: 1999399
- Crockford D. "Development of thymosin beta4 for treatment of patients with ischemic heart disease." Ann N Y Acad Sci. 2007;1112:385-95. PMID: 17468262
- Huff T, et al. "beta-Thymosins, small acidic peptides with multiple functions." Int J Biochem Cell Biol. 2001;33(3):205-20. PMID: 11311851
- Malinda KM, et al. "Thymosin beta4 accelerates wound healing." J Invest Dermatol. 1999;113(3):364-8. PMID: 10469334
- Sosne G, et al. "Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury." Exp Eye Res. 2002;74(2):293-9. PMID: 12091418
- Bock-Marquette I, et al. "Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair." Nature. 2004;432(7016):466-72. PMID: 15538359
- Smart N, et al. "Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization." Nature. 2007;445(7124):177-82. PMID: 17108969
- Sosne G, et al. "Thymosin beta 4 and corneal wound healing." Vitam Horm. 2011;87:187-97. PMID: 22127242
- Philp D, et al. "Thymosin beta4 promotes matrix metalloproteinase expression during wound repair." J Cell Physiol. 2006;208(1):195-200. PMID: 16575910
- Smart N, et al. "Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart." Ann N Y Acad Sci. 2010;1194:97-104. PMID: 20536455
- Philp D, et al. "Thymosin beta4 increases hair growth by activation of hair follicle stem cells." FASEB J. 2004;18(2):385-7. PMID: 14657001
Related Pages
Concise compound overview
Step-by-step research protocol
Top stack partner deep-dive
Combined protocol guide
Precise dosing calculations
Monitor active trials
Medical Disclaimer: This article is for educational and research reference purposes only. TB-500 is not approved by any regulatory agency for human use. All information is derived from preclinical research and limited clinical trials of pharmaceutical-grade thymosin beta-4. Consult a qualified healthcare professional before considering any research compound. See our full Medical Disclaimer.
